Nathaniel is an intellectual property litigator. His practice focuses on contentious legal issues confronting innovation-intensive industries, with an emphasis on patent and regulatory issues facing pharmaceutical and biotechnology companies.
Nathaniel has represented numerous companies in the life sciences, technology, energy and gaming industries in patent proceedings across Canada and pro hac vice in the United States. He has also litigated trade-mark, copyright, trade secret and other commercial matters. Nathaniel was lead counsel for the Children’s Hospital of Eastern Ontario, in Canada’s only patent litigation involving claims to human genes, representing the hospital pro bono. He has also advocated on behalf of life sciences clients before numerous regulatory agencies in Canada and the United States on intellectual property, regulatory approval, pricing and reimbursement, and antitrust matters.
Nathaniel is a registered patent and trade-mark agent. In addition to his role as advocate, Nathaniel provides strategic advice on intellectual property portfolio and risk management, including in the context of IP transactions. He has assisted companies in a variety of innovation-intensive industries, including early-stage businesses, by coordinating intellectual property, regulatory and commercial strategies. Nathaniel also has a depth of experience advising on international trade-related intellectual property matters.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020
Keynote Panel Discussion:
Inform your Market Access Strategy with Cross-Border Perspectives on CUSMA, Affordable Drug Prices and Access to Prescription Medicine during Covid-19 and Beyond
One of the consequences of Covid-19 is the problem many people have accessing prescription medication in both Canada and the U.S. because of unemployment and escalating drug costs. Both Canada and the U.S. have taken steps to address rising costs, so far with limited success. CUSMA will also have an impact on access going forward. Gain key insights on:
- The impact CUSMA may have on IP and Canada’s listing on the ‘Watch List’ of the Office of the U.S. Trade Representative
- Canada’s future prospects of gaining access to vaccines for Covid-19
- Progress of drug price containment initiatives of both Canada and the U.S.
Sharpen your North American market access strategies with key insights on cross-border issues